Drug Trial Radar · NCT00444275
Nexium (Esomeprazole) in Symptom Adapted Therapy in GERD Patients
Last checked: Nov 19, 2026Latest source record: Dec 11, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
3,029
Actual
Start
Mar 2007
Primary completion
Oct 2008
Study completion Oct 2008
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Mar 7, 2007
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To compare the efficacy of three different long-term treatment strategies of reflux disease in primary care setting.
Conditions
- GERD
Interventions
esomeprazole (Nexium®)Drug
This randomized study was conducted on parallel groups and included two phases: * One initial phase during when the patients received once daily, either esomeprazole 20 mg or esomeprazole 40 mg, depending on the investigator's decision * One maintenance treatment phase, patients were randomized to one of the following three groups, either esomeprazole 20 mg once daily, or esomeprazole 20 mg on demand or antacid treatment as needed
Xolaam®Drug
This randomized study was conducted on parallel groups and included two phases: * One initial phase during when the patients received once daily, either esomeprazole 20 mg or esomeprazole 40 mg, depending on the investigator's decision * One maintenance treatment phase, patients were randomized to one of the following three groups, either esomeprazole 20 mg once daily, or esomeprazole 20 mg on demand or antacid treatment as needed
Primary outcomes
What the sponsor says the trial is designed to measure.
- Efficacy of Three Strategies of Long-term TreatmentTime frame: 16 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Research Site
Rouen, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.